HELP

CybinF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.50

Analysis reference price unavailable

Analysis 2026-07-09 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$6.00

Analysis reference price unavailable

Analysis 2026-07-09 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$3.25

Analysis reference price unavailable

Analysis 2026-07-09 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-09

AI commentary

Primary company materials in the stored earnings context support the June 29, 2026 fiscal-year update and pipeline milestones, but the broader evidence set remains thin. The stock anchor was $6.23 on July 8, 2026. With no usable social packet, no SEC excerpt in the packet, limited external coverage, and only loose same-sector micro-cap peer candidates, sentiment should be treated as cautious monitoring rather than a standard-conviction directional setup.

RankAlpha Sentiment Codex - 2026-07-09

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystPost-offering cash reduces immediate financing pressure but dilution remains part of the setupHigh impact

Primary company materials show $157.3 million of cash at March 31, 2026 and completion of a $50 million underwritten offering on June 25, 2026; that helps near-term runway, but the equity-financed model keeps dilution and future capital needs in focus [#PR-EARNINGS-2026-06-29].

2026-12-15eventHLP003 Phase 3 APPROACH topline data targeted for Q4 2026High impact

Helus Pharma, the commercial operating name of Cybin Inc., said the APPROACH pivotal Phase 3 study in MDD has surpassed 88% enrollment and remains on track for a Q4 2026 topline readout, which is the clearest binary value driver in the packet [#PR-EARNINGS-2026-06-29].

2028-06-30catalystSecond Phase 3 study and 2028 NDA path can extend upside if execution holdsHigh impact

The company said the June 2026 financing is intended to support EMBRACE, the second Phase 3 HLP003 trial, with a potential U.S. NDA path in 2028; that adds duration to the thesis but remains heavily execution-dependent for a micro-cap biotech [#PR-EARNINGS-2026-06-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-09 • Updated nightlySource: Internal modelMethodology